Understanding Disparities in Quitting in African American and White Smokers

• Status: Completed
• Trial end date: 2017-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to describe the differences in quitting smoking between African Americans (AA) and White smokers treated with varenicline.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nikki Nollen, PhD, MA
• Collaborators: National Institute on Drug Abuse (NIDA); Pfizer
• Treatments: Varenicline

Criteria

Inclusion Criteria:

• Non-Hispanic African American or non-Hispanic White

• ≥ 18 years of age

• Smoked 3-20 cigarettes per day

• Smoked on >25 days of the past 30 days

• Functioning telephone

• Interested in quitting smoking

• Interested in taking 3 months of varenicline

• Willing to complete all study visits

Exclusion Criteria:

• Renal impairment

• Evidence or history of clinically significant allergic reactions to varenicline

• A cardiovascular event in the past month Hospitalization in the past 2 months for any cardiovascular disease, including but not limited to:

• Angina

• Myocardial infarction

• Peripheral vascular disease

• Stroke

• New onset of chest pain or arrhythmia in the past 2 months

• History of alcohol or drug dependency in the past year

• Major depressive disorder in the last year requiring treatment

• History of panic disorder, psychosis, bipolar disorder, or eating disorders

• Use of tobacco products other than cigarettes in past 30 days

• Use of pharmacotherapy in the month prior to enrollment, including prior use of varenicline

• Pregnant, contemplating getting pregnant, or breastfeeding

• Plans to move from Kansas City during the treatment and follow-up phase

• Another household member enrolled in the study